RegenxbioFRA:RB0 +12.26%54 PB Ratio is 36.83 as of Jul. 07, 2026, which is 1201% above its 10-year median of 2.83. GuruFocus rates FRA:RB0 with a GF Score™ of 54/100 and a GF Value™ of €12.61 (Fairly Valued). The stock has 9 warning signs investors should review. Among 1,226 Biotechnology companies, Regenxbio ranks worse than 96.08% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Regenxbio's share price is €13.00. Regenxbio's Book Value per Share for the quarter that ended in Mar. 2026 was €0.35. Hence, Regenxbio's PB Ratio of today is 36.83.
Warning Sign:
Regenxbio Inc stock PB Ratio (=36.35) is close to 10-year high of 36.35.
The historical rank and industry rank for Regenxbio's PB Ratio or its related term are showing as below:
FRA:RB0'
s PB Ratio Range Over the Past 10 Years
Min: 1.07 Med: 2.83 Max: 36.35
Current: 36.35
During the past 13 years, Regenxbio's highest PB Ratio was 36.35. The lowest was 1.07. And the median was 2.83.
FRA:RB0's PB Ratio is ranked worse than 96.08% of 1226
companies
in the Biotechnology industry
Industry Median: 2.91
vs FRA:RB0: 36.35
During the past 12 months, Regenxbio's average Book Value Per Share Growth Rate was -92.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -44.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -29.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Regenxbio was 25.80% per year. The lowest was -44.70% per year. And the median was 3.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Regenxbio PB Ratio Related Terms
Regenxbio PB Ratio Historical Data
* Premium members only.
The historical data trend for Regenxbio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regenxbio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenxbio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenxbio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Regenxbio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Regenxbio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Regenxbio (FRA:RB0) has a PB Ratio of 36.83 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regenxbio and its competitors. This is 1201% above median its historical median of 2.83. Over the past decade, Regenxbio's PB Ratio has ranged from 1.07 to 36.35. According to the industry distribution chart, Regenxbio ranks #1178 out of 1226 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Regenxbio's PB Ratio too high?
Regenxbio's current PB Ratio of 36.83 is 1201% above median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 36.35. The Biotechnology industry median PB Ratio is 2.91. Regenxbio's value of 36.83 is 1165.6% above this industry median. Based on the distribution chart, Regenxbio ranks #1178 out of 1226 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Regenxbio has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's PB Ratio compare to ALT and ASMB?
According to the Biotechnology industry distribution chart, Regenxbio ranks #1178 out of 1226 companies for PB Ratio. This places Regenxbio in the lower half of its industry. The industry median PB Ratio is 2.91. Regenxbio's value of 36.83 is 1165.6% above this benchmark. Historically, Regenxbio's own PB Ratio has ranged from 1.07 to 36.35 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 2.91, Regenxbio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenxbio's current PB Ratio of 36.83 is 1165.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regenxbio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenxbio's current PB Ratio is 36.83, which is 1201% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (FRA:RB0) is currently considered Fairly Valued. The stock's GF Value™ is €12.61, compared to a current price of €13.00 — trading 3.1% above its estimated fair value. The current PB Ratio is 36.83, which is 1201% above median its 10-year median of 2.83 and 1165.6% above the Biotechnology industry median of 2.91. Regenxbio's overall GF Score™ is 54/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Regenxbio (FRA:RB0), the current PB Ratio is 36.83 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regenxbio (FRA:RB0) Overvalued in 2026?
Based on GuruFocus' analysis, Regenxbio stock appears to be overvalued.
The current stock price of €13.00 is trading 3.1% above its estimated GF Value™ of €12.61.
GuruFocus considers Regenxbio to be Fairly Valued.
Key valuation signals for FRA:RB0:
PB Ratio: 36.83 (1201% above median its 10-year median of 2.83)
GF Value™: €12.61 vs. price of €13.00 (3.1% above fair value)
Industry Position: 1165.6% above the Biotechnology median (#1178 of 1226)
No single metric tells the full story. See the FRA:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
54GF Score
Get the complete analysis for FRA:RB0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RB0 has been successfully added to your 
